In a report issued on July 15, Luca Issi from RBC Capital maintained a Buy rating on Caribou Biosciences (CRBU – Research Report), with a price target of $22.00. The company’s shares closed last Monday at $6.73, close to its 52-week low of $4.89.
According to TipRanks.com, Issi is ranked 0 out of 5 stars with an average return of -19.7% and a 27.5% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, BioMarin Pharmaceutical, and Adverum Biotechnologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Caribou Biosciences with a $26.25 average price target, which is a 262.1% upside from current levels. In a report issued on July 12, SVB Securities also reiterated a Buy rating on the stock.
Caribou Biosciences’ market cap is currently $434.7M and has a P/E ratio of -5.92.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRBU in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.
Read More on CRBU: